Pipeline

February 7, 2020
Company Drug/Device Medical Condition Status
Asklepios BioPharmaceutical NAN-101 congestive heart failure phase 1 trial dosing first patient
Immix Biopharma Imx-110 advanced solid tumors phase 1b/2a trial dosing first patient in U.S.
Moleculin Biotech Liposomal Annamycin (annamycin) relapsed or refractory acute myeloid leukemia phase 1 trial completed
AIVITA Biomedical AV-GBM-1 glioblastoma phase 2 trial enrollment completed
Alkahest AKST4290 Parkinson’s Disease phase 2 trial dosing first patient
Minerva Neurosciences roluperidone schizophrenia phase 3 trial enrolling 515 patients in the U.S. and Europe
INVO Bioscience INVOcell infertility phase 3 trial enrolling 180 patients at three sites in the U.S.
VistaGen Therapeutics AV-101 dyskinesia in Parkinson's Disease patients phase 2 IND awarded by the FDA
GlycoMimetics GMI-1359 osteosarcoma Orphan Drug and Rare Pediatric Disease designations granted by the FDA
Aria CV Aria CV Pulmonary Hypertension System pulmonary arterial hypertension Breakthrough Device designation awarded by the FDA
ReAlta Life Sciences PIC1-dPEG24 hypoxic-ischemic encephalopathy in neonates Orphan Drug designation awarded by the FDA
EyeYon Medical EndoArt film implant chronic corneal edema secondary to endothelial dysfunction Breakthrough Device designation awarded by the FDA
VIVUS PANCREAZE (pancrelipase) Delayed Release Capsules exocrine pancreatic insufficiency due to cystic fibrosis or other conditions supplemental NDA approved by the FDA
Seqirus Audenz vaccine potential pandemic associated with the H5N1 flu virus approved by the FDA
Aimmune Therapeutics Palforzia (AR101) pediatric patients, ages 4 to 17, who have an allergy to peanuts approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here